Celcuity at guggenheim healthcare innovation conference: launch gains pace

Celcuity, a precision oncology company, recently launched its cancer drug REVTORPYK at the Guggenheim Healthcare Innovation Conference. The drug, approved for patients with second-line HR-positive, HER2-negative advanced breast cancer, is gaining early traction and is being ordered by 80% of strategic accounts about six weeks after its launch.

Celcuity's newly launched cancer drug REVTORPYK is gaining early traction, even as the company works through reimbursement, manufacturing and international expansion issues. The precision oncology company also pointed to a broader pipeline in breast and prostate cancer that it says could support much larger revenue over time.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.